Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+45.5%
5Y CAGR+66.5%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+45.5%/yr
vs +38.1%/yr prior
5Y CAGR
+66.5%/yr
Recent deceleration
Acceleration
+7.4pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
12.8x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $119.39M | +14.2% |
| 2024 | $104.55M | +25.2% |
| 2023 | $83.53M | +115.3% |
| 2022 | $38.79M | +56.7% |
| 2021 | $24.76M | +165.7% |
| 2020 | $9.32M | -61.3% |
| 2019 | $24.08M | +125.6% |
| 2018 | $10.68M | +19.9% |
| 2017 | $8.90M | - |